Dr. Lei Stanley Qi is associate professor in the Department of Bioengineering, a faculty fellow in Stanford ChEM-H, and a Chan Zuckerberg Biohub Investigator. Dr. Qi is one major contributor to the development of CRISPR technologies for genome engineering. He developed the first use of nuclease-deactivated Cas9 (dCas9) for sequence-targeted gene regulation in prokaryotic and eukaryotic cells. His lab invents a broad CRISPR toolbox for manipulating the human genome, including technologies for gene regulation (CRISPRi and CRISPRa), epigenome engineering, live cell DNA/RNA imaging (LiveFISH), 3D genome manipulation (CRISPR-GO), CRISPR antivirals for SARS-CoV-2 (PAC-MAN), and miniature CRISPR (CasMINI) for gene therapy. His lab combines synthetic biology with genome engineering to study the function of the genome and develop novel gene therapy. He obtained B.S. in Physics from Tsinghua University, Ph.D. in Bioengineering from the University of California Berkeley, and was a UCSF Systems Biology Faculty Fellow. He joined the faculty at Stanford University in 2014.
